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Fractures, bone mineral density 
A B S T R A C T   
Objectives: This study sought to identify the clinical and biochemical characteristics that would help distinguish 
hypophosphatasia (HPP) from other metabolic bone diseases in adult patients attending a metabolic bone clinic 
by comparing patients who have genetically confirmed HPP with a group of patients with low bone mineral 
density (BMD) in the osteoporotic or osteopenic range. 
Methods: Data were collected from February 2016 to October 2018 for 41 patients (n = 20 in the HPP group, n =
21 in the low-BMD group) attending the metabolic bone clinic at Sheffield, United Kingdom (UK) or who were 
recruited via the Rare UK Diseases Study (RUDY) platform during the same period. A study questionnaire was 
administered to all patients, and assessments were conducted for laboratory values, physical functions, BMD, and 
spine imaging. 
Results: Patients with HPP were characterized as being younger, more likely to have metatarsal or femoral shaft 
fractures, and less likely to have vertebral fractures compared with patients in the low-BMD group. The HPP 
group had lower total and bone-specific alkaline phosphatase, higher pyridoxal 5′-phosphate (PLP), and lower, 
albeit sufficient, 25-hydroxyvitamin D. Low-BMD group had lower C-terminal telopeptide and tartrate-resistant 
acid phosphatase 5b (61.9% were on bisphosphonates at enrollment). Dual X-ray absorptiometry (DXA) analysis 
found that the HPP group had higher total hip and lumbar BMD T- and Z-scores compared with the low-BMD 
group. There were no differences found between the two groups with physical functional assessments. Results 
of receiver operating characteristic analysis indicated strong diagnostic accuracy of these biomarkers for HPP. 
Thresholds of total alkaline phosphatase (ALP) activity of 43 IU/L or less and PLP level of 120 nmol/L or more 
were determined to be potentially clinically useful for distinguishing HPP from other metabolic bone diseases. 
Conclusion: This study supported the use of ALP and PLP measurements as predictive of HPP diagnosis along with 
certain demographic and clinical characteristics (younger age, metatarsal or femoral fractures without low mean 
BMD T- and Z-scores on a DXA scan) that can aid in recognizing adults who should be further evaluated for HPP. 
The critical values identified need to be applied to an independent sample to be tested for diagnostic accuracy.   
Abbreviations: 25D, 25-hydroxyvitamin D; ALP, alkaline phosphatase; ALPL, alkaline phosphatase, biomineralization-associated; BAP, bone-specific ALP; BMD, 
bone mineral density; CTX, C-terminal telopeptide; DXA, dual X-ray absorptiometry; HPP, hypophosphatasia; HRQoL, health-related quality of life; LSBMD, lumbar 
spine BMD; OC, osteocalcin; PINP, procollagen type I N-propeptide; PLP, pyridoxal 5′-phosphate; PTH, parathyroid hormone; RI, reference interval; ROC, receiver 
operating characteristic; RUDY, Rare UK Diseases Study; SD, standard deviation; SPPB, Short Physical Performance Battery; TNSALP, tissue-nonspecific alkaline 
phosphatase; TRACP5b, tartrate-resistant acid phosphatase 5b; UK, United Kingdom. 
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1. Background 
Hypophosphatasia (HPP) is a rare, inherited, metabolic disease that 
is caused by low activity of tissue-nonspecific alkaline phosphatase 
(TNSALP), due to alkaline phosphatase biomineralization-associated 
(ALPL) gene mutations [1,2]. Deficient activity of TNSALP leads to the 
extracellular accumulation of several TNSALP substrates such as inor-
ganic pyrophosphate, a potent inhibitor of bone mineralization, and 
pyridoxal 5′-phosphate (PLP), the active form of vitamin B6. Due to the 
accumulation of these substrates, HPP can manifest at any age with a 
range of symptoms, including premature loss of teeth, HPP-related 
rickets (in infants and children), osteomalacia with associated frac-
tures and pseudofractures (particularly in adults), pain, muscle weak-
ness, and ambulatory difficulties among other symptoms (eg, vitamin 
B6-dependent seizures and respiratory difficulties in infants, knee pain 
from chondrocalcinosis, neurologic or rheumatologic complaints in 
adults) [2,3]. These symptoms can have a detrimental effect on the 
health-related quality of life (HRQoL) of adults with HPP, because of 
their impact on daily activities [4]. 
The heterogenous clinical presentation of HPP creates many chal-
lenges in diagnosing the disease. Certain signs, symptoms, or compli-
cations of HPP can change during a patient’s lifetime [5]. Although HPP 
can be diagnosed during adulthood (age ≥ 18 years), adults may have 
histories of signs or symptoms before 18 years of age but their disease 
was not recognized during childhood. In fact, adults with HPP 
frequently experience substantial delays in diagnosis [3,6,7]. Moreover, 
HPP in adults may be misdiagnosed as osteoporosis due to similar 
symptoms such as frequent fractures of the lower extremities [2]. 
Misdiagnosis or delayed diagnosis may lead to worsening of HPP-related 
manifestations and the patient’s general health [8,9]. In addition, 
initiating treatment for osteoporosis with bisphosphonates, pharma-
ceutical analogs of inorganic pyrophosphate, may exacerbate HPP 
symptoms and increase the risk of atypical femoral fractures [10–12]. 
Limited disease awareness and heterogeneity of symptoms are some 
of the major contributing factors to the late diagnosis or misdiagnosis of 
HPP in adults. However, robust biomarker thresholds can assist in 
recognizing possible cases of HPP, and genetic testing may be useful in 
confirming the diagnosis. Therefore, this study utilized clinical charac-
teristics and biochemical markers, supplemented by genetic testing, as 
diagnostic tools to aid in distinguishing adults with HPP from adults 
with other metabolic bone diseases, with the aim of raising awareness 
about diagnostic criteria for HPP in adults. 
2. Materials and methods 
2.1. Study design 
This was a prospective study of adults (age ≥18 years) who attended 
the Metabolic Bone Centre at the Northern General Hospital, Sheffield, 
United Kingdom (UK), or were recruited via the Rare UK Diseases Study 
(RUDY) platform between February 2016 and October 2018 [13]. The 
study was approved by the North West-Greater Manchester East 
Research Ethics Committee, REC number: 16/NW/0385. All patients 
provided informed written consent prior to study participation. 
2.2. Patients 
All patients had genetic assessments by the Sheffield Children’s 
Hospital Clinical Genetics Laboratory, using next-generation sequencing 
confirmed by Sanger sequencing. Two groups of patients were selected 
for the study: adults who had a confirmed diagnosis of HPP (HPP group) 
and adults who had low bone mineral density (BMD) and attended the 
Sheffield Metabolic Bone Centre for osteoporosis (low-BMD group). 
Adult patients were eligible to be included in the HPP group if they 
had persistently low alkaline phosphatase (ALP) activity and the clinical 
presentation of musculoskeletal symptoms consistent with HPP. As part 
of the study protocol, the diagnosis of HPP was confirmed with genetic 
assessments that identified ALPL gene variants that were pathogenic or 
likely pathogenic mutations based on the American College of Medical 
Genetics and Genomics criteria. Patients were eligible for the low-BMD 
group if BMD was in the osteoporotic or the osteopenic range, if the 
genetic assessment identified no ALPL gene variants, and if ALP activity 
was not persistently low. The osteoporotic range was defined as T-score 
≤−2.5 for lumbar spine BMD (LSBMD) or total hip BMD [14]; the 
osteopenic range was defined as T-score <−1.0 for LSBMD [14] or total 
hip BMD in patients who did not have osteoporosis. Patients in the low- 
BMD group were compared with patients in the HPP group (Fig. 1). 
Because patients with HPP are typically younger than those with oste-
oporosis, it was difficult to individually match patients by age using a 
statistical method, such as propensity score matching. Therefore, the 
two groups were comprised from the pool of patients who met all in-
clusion criteria and were available via the Sheffield Metabolic Bone 
Centre and RUDY platform. 
At study enrollment, investigators used a standard metabolic bone 
questionnaire for patients to capture general information relating to 
bone health, such as the use of medications (including bisphospho-
nates), medical history, and baseline clinical characteristics. Patients in 
the HPP group were also assessed for pediatric-onset (aged <18 years) or 
adult-onset (aged ≥18 years) HPP based on the reported age of the first 
signs and symptoms of HPP. The specific signs and symptoms were 
assessed by investigators based on established literature and included 
premature loss of teeth [2,15,16]. 
2.3. Laboratory analysis 
Blood samples were drawn from patients in the fasting state, and 
because PLP levels were being assessed, patients were required to stop 
taking vitamin supplements (if any) for more than 3 weeks. Samples 
were serum separated, stored at −70 ◦C, and analyzed in a single batch 
(at the Chemical Pathology Laboratory, Sheffield Teaching Hospital 
National Health Service Foundation Trust) for total ALP activity, cal-
cium, and phosphate levels using a Roche/Hitachi Cobas 8000 e702 
automated clinical chemistry analyzer (Roche Diagnostics GmbH, 
Mannheim, Germany). Samples were also analyzed in the Bone 
Biochemistry Laboratory at the University of Sheffield for bone resorp-
tion markers and bone formation markers using an iSYS automated 
immunoassay system (Immunodiagnostics Ltd., Boldon, UK). The 
analyzed bone resorption markers were tartrate-resistant acid phos-
phatase 5b (TRACP5b) and C-terminal telopeptide (CTX), and the bone 
formation markers were bone-specific ALP (BAP), procollagen type I N- 
propeptide (PINP), osteocalcin (OC), 25-hydroxyvitamin D (25D), and 
parathyroid hormone (PTH). Serum PLP levels were measured using 
cation-exchange high-performance liquid chromatography (Chromsys-
tems Instruments and Chemicals GmbH, Munich, Germany) [17,18]. 
Reference intervals were established in 200 healthy women (mean 
age 39 years, standard deviation [SD]: 4 years, range 30 to 45 years) and 
92 healthy men (mean age 47 years, SD: 21 years, range 16 to 77 years). 
All healthy subjects also stopped taking vitamin supplements before 
testing for PLP, as described above for the study population. The lower 
limit of the interval was established at 4.2 μg/L for BAP. The upper limit 
of the interval for PLP differed by sex and was 177.9 nmol/L for women 
and 250.7 nmol/L for men. The lower limit of the reference interval for 
total ALP activity was 30 IU/L. the reference interval for all laboratory 
assays is provided in Table 2. 
2.4. Fracture and bone assessments 
LSBMD and total hip BMD were assessed by dual X-ray absorpti-
ometry (DXA) using a Discovery A densitometer (Hologic Inc., Waltham, 
MA). For each group, both T- and Z-scores were calculated based on 
established criteria [14]. The presence of vertebral fractures in the 
lateral DXA image of the spine was assessed using an algorithm-based 
R. Desborough et al.                                                                                                                                                                                                                            
Bone 144 (2021) 115795
3
qualitative approach [19]. 
2.5. Functional assessments 
Patients’ physical function was assessed using the grip strength test 
(digital hand dynamometer, Seehan Corporation, Masan, Korea) and the 
Short Physical Performance Battery (SPPB) [20]. Low grip strength was 
identified as less than 16 kg in women and less than 27 kg in men [21]. 
Scores for the SPPB are based on patients’ performances on the chair 
rise, tandem balance, and the 8-foot walk tests. Patients were classified 
as frail (SPPB 0–6), pre-frail (SPPB 7–9), or non-frail (SPPB 10–12) based 
on SPPB scores [22]. 
2.6. Receiver operating characteristic (ROC) analysis 
Sensitivity and specificity of total ALP, BAP, and PLP as diagnostic 
tools to recognize HPP in adult patients were calculated using ROC 
analysis. Maximum diagnostic likelihood ratios were also calculated 
using ROC analysis. 
2.7. Data analysis 
Wizard version 1.9.30 (Free Software Foundation, Boston, USA) and 
Prism for MacOS X version 7c (GraphPad Software Inc., CA, USA) sta-
tistical software were used for the data analysis. MedCalc version 16.8.4 
(MedCalc, Ostend, Belgium) software was used to calculate 95% refer-
ence intervals (RIs). Variables were summarized with n, mean, and SD. 
Comparisons between patient groups were assessed using P values, 
which were calculated using multiple linear regression with group, age, 
and sex as covariates. 
3. Results 
3.1. Patient demographics and baseline clinical characteristics 
Overall, 41 adult patients (66% women) were included in the study. 
The population was comprised of 21 patients in the low-BMD group and 
20 patients in the HPP group. Patients in the low-BMD group were 
recruited via the Sheffield Metabolic Bone Centre. Of the 20 patients in 
the HPP group, 12 were recruited via the Sheffield Metabolic Bone 
Centre and 8 were recruited via the RUDY platform (Fig. 1). All patients 
in the HPP group had an ALPL pathogenic or likely pathogenic variant, 
as confirmed by genetic assessment. Three patients in the HPP group had 
compound heterozygous variants in ALPL. Genetic profiles of each of the 
20 patients with HPP are available in Supplementary material 1. An 
assessment of the age of onset revealed that 7 (35%) patients in the HPP 
group had pediatric-onset HPP and 13 (65%) patients had adult-onset 
HPP. 
Patient demographics and characteristics of the study population are 
presented in Table 1. Patients in the HPP group were generally younger 
than those in the low-BMD group. Bisphosphonate use at study enroll-
ment was more prevalent in the low-BMD group (61.9% of patients) 
than in the HPP group (0.0% of patients). In addition, patients in the 
HPP group were not exposed to asfotase alfa nor teriparatide or stron-
tium, which could have affected ALP levels. 
3.2. Fracture and bone assessments 
Metatarsal/foot and femoral shaft fractures occurred more 
frequently among patients in the HPP group versus those in the low- 
BMD group. No patients in the low-BMD group had experienced meta-
tarsal/foot or femoral shaft fractures, whereas 5 (25%) patients in the 
HPP group had experienced metatarsal/foot fractures and 2 (10%) pa-
tients experienced femoral shaft fractures (Fig. 2). In contrast, vertebral 
fractures were more common in the low-BMD group versus the HPP 
group (6 and 0, or 29% vs 0%, respectively). 
Of note, one patient with compound heterozygous ALPL variants and 
pediatric-onset HPP was severely affected, reporting 9 total factures, 
including a right femur fracture at the age of 34 years and later expe-
riencing the recurrence of stress fractures in the metatarsals of both feet 
and one radius. The other two patients with compound heterozygous 
ALPL variants, one with pediatric-onset HPP and one with adult-onset 

















Fig. 1. Study population. 
aAdults with a clinical diagnosis of HPP, confirmed 
by genetic assessments, were eligible to be enrolled 
in the HPP group. 
bPatients were eligible for the low-BMD group if BMD 
was in the osteoporotic or osteogenic range. 
BMD, bone mineral density; HPP, hypophosphatasia; 
RUDY, Rare UK Diseases Study.   
Table 1 
Patient demographics and clinical characteristics of the study population.  
Characteristic HPP group 
n = 20 
Low-BMD group 
n = 21 
Women 
n = 12 
Men 
n = 8 
Women 
n = 15 
Men 
n = 6 










Mean weight, kg 
(SD) 
77.6 (27.0) 89.7 (23.1) 68.9 (15.7) 85.9 (7.7) 
Mean height, cm 
(SD) 
166.4 (9.3) 175.8 (8.1) 160.9 (5.8) 175.4 (4.0) 
Treatment at 
enrollment, n (%) 
Bisphosphonates   0 (0.0)   13 (61.9) 
BMD, bone mineral density; HPP, hypophosphatasia; SD, standard deviation. 
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Total hip and LSBMD T-scores were significantly higher among pa-
tients in the HPP group, and within the normal range, versus those in the 
low-BMD group, which were below the normal range (P < 0.01 and P <
0.001, respectively; Table 2). Total hip and LSBMD Z-scores were also 
significantly higher among patients in the HPP group versus those in the 
low-BMD group (P < 0.001 and P < 0.001, respectively; Table 2) but 
were at the expected level for their age (mean Z-score close to zero). 
3.3. Laboratory analysis 
Consistent with the inclusion criteria, total ALP and BAP activities 
were significantly lower in the HPP group vs the low-BMD group (both P 
< 0.001, Table 2). The level of PLP was significantly higher among 
patients in the HPP group when compared with those in the low-BMD 
group (P < 0.01). Notably, total ALP was 3-fold lower and PLP was 7- 
fold higher in patients with HPP when compared with those in the 
low-BMD group. TRACP5b and CTX were significantly lower among 
patients in the low-BMD group when compared with those in the HPP 
group (both P < 0.01). No significant differences in the levels of PINP, 
OC, PTH, calcium, and phosphate were observed between the two 
groups. When comparing women and men of the two groups, no sig-
nificant differences in biomarkers were observed (data not shown). 
Additional laboratory analyses showed that a total ALP activity of 43 
IU/L or less, in the presence of additional clinical features consistent 
with a diagnosis of HPP, could be used as an appropriate threshold to 
distinguish patients with HPP from control patients with osteoporosis. 
This threshold would classify all patients in the HPP group and 19 (of 
21) patients in the low-BMD group correctly (Fig. 3). Notably, using this 
ALP activity threshold with an additional requirement of PLP ≥ 120 
nmol/L would classify all patients in the HPP and low-BMD groups 
correctly (Fig. 3). 
3.4. Functional assessments 
There were no significant differences in grip strength and SPPB 
scores between patients in the HPP group versus those in the low-BMD 
group (all P ≥ 0.05). Twelve patients (n = 8 women, n = 4 men) from 
the low-BMD group and 11 patients (n = 7 women, n = 4 men) from the 
HPP group had low grip strength classified by the predefined grip 
strength test thresholds. Frail, pre-frail, and non-frail SPPB scores were 
identified in 1, 9, and 10 patients of the HPP group and 3, 5, and 13 
patients of the low-BMD group, respectively. 
3.5. ROC analysis 
Results of the ROC analysis are presented in Fig. 4. The area under 
the ROC curves for total ALP, BAP, and PLP were 0.991 (95% confidence 

































HPP group Low BMD group
Fig. 2. Fracture prevalence among patients in the HPP and low-BMD groups. 
BMD, bone mineral density; HPP, hypophosphatasia. 
Table 2 
Biochemistry and total hip and lumbar BMD results for patients in the HPP and 




n = 20 
Low-BMD 
group 
n = 21 
Total ALP, IU/Lb Adult: 30–130 23.8 (8.8)*** 73.1 (32.3) 
BAP, μg/Lb Women: 4.2–24.3 6.3 (3.1)*** 18.6 (10.5) 
PINP, μg/Lb Women: 
15.5–78.6 
51.3 (26.4) 38.1 (20.8) 







TRACP5b, IU/Lb Women: 1.5–4.9 2.8 (1.4)** 1.8 (1.0) 




OC, μg/Lb Women: 5.5–29.3 11.2 (4.5) 9.2 (4.8) 
PTH, ng/Lb 7.0–69.0 [38] 23.1 (16.4) 19.4 (13.3) 





2.4 (0.1) 2.3 (0.1) 
Phosphate, mmol/Lb Adult: 0.8–1.5 
[39,40] 
1.4 (0.3) 1.2 (0.2) 
LSBMD, T-scoreb – −0.6 (1.9)*** −2.3 (0.9) 
Total hip BMD, T- 
scoreb 
– −0.4 (1.0)** −1.4 (0.8) 
LSBMD, Z-scoreb – 0.1 (2.0)*** −1.6 (1.4) 
Total hip BMD, Z- 
scoreb 
– 0.0 (1.0)*** −0.7 (1.0) 
ALP, alkaline phosphatase; BAP, bone-specific alkaline phosphatase; BMD, bone 
mineral density; CTX, C-terminal telopeptide; HPP, hypophosphatasia; LSBMD, 
lumbar spine bone mineral density; OC, osteocalcin; PINP, procollagen type I N- 
propeptide; PLP, pyridoxal-5-phosphate; PTH, parathyroid hormone; RI, refer-
ence interval; SD, standard deviation; TRACP5b, tartrate-resistant acid phos-
phatase 5b; 25D, 25-hydroxyvitamin D. 
a Reference intervals established in the current study are listed in the table 
unless otherwise cited. 
b Mean (SD) is reported and comparisons between the two groups were con-
ducted using multiple linear regression analysis adjusted for age and sex. Sig-
nificant P values (P < 0.05) are shown in the table. 
c Median (interquartile range) is reported and comparisons between the two 
groups were conducted using a Mann–Whitney U test due to outliers in the data. 
Significant P values (P < 0.05) are shown in the table. 
* P < 0.05. 
** P < 0.01. 
*** P < 0.001. 
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(0.965–1.000), respectively, indicating strong diagnostic accuracy of 
these biomarkers for HPP. In addition, the maximum diagnostic likeli-
hood ratio values were 36.5 IU/L, 10.1 μg/L, and 182 nmol/L for total 
ALP, BAP, and PLP, respectively. 
4. Discussion 
Adults with HPP may present with a wide range of clinical mani-
festations, including fractures, pain, muscle weakness, and gross motor 
difficulties that often overlap with other metabolic bone diseases 
[2,15,16,23]. Consequently, adults with HPP have commonly been un-
diagnosed or misdiagnosed for osteomalacia related to other causes, 
osteopenia, and/or osteoporosis [2,24]. This results in a delay of initi-
ating treatment or even incorrect management of HPP, which can 
impact quality of life [3,4]. The present analysis has described and 
quantified clinical and biochemical indicators of HPP that could be used 
in clinical practice to assist in distinguishing and diagnosing patients 
who have HPP from patients who do not have HPP but present with 
similar symptoms. 
In the current study, we identified several demographic and clinical 
characteristics that were common in adults with HPP. Specifically, 
patients with HPP were younger and had more metatarsal and femoral 
shaft fractures, but fewer vertebral fractures, when compared with pa-
tients in the low-BMD group. The main sites of fracture were metatarsal 
and femoral, which is consistent with the findings from other studies 
[3,23,25]. Chondrocalcinosis may also be helpful in distinguishing HPP 
from osteoporosis [26]; however, in this study, no patients had evidence 
of chondrocalcinosis (knee pain/soreness and/or radiographic features). 
DXA results indicated higher BMD T- and Z-scores for the total hip and 
lumbar spine in patients with HPP when compared with patients who 
had low BMD. Other studies have found BMD T-scores to be either at or 
above the expected level for age, with high LSBMD being one of the risk 
factors for femoral fractures [23], or only slightly reduced in patients 
with HPP [27,28]. These results should alert a clinician to a diagnosis of 
HPP if a younger patient demonstrates clinically increased bone fragility 
in the absence of low BMD. 
This study also evaluated biochemical markers that could be used to 
distinguish patients with HPP from those with low BMD. Reduced serum 
ALP activity, elevated levels of PLP, and reduced BAP activity are well- 
known biomarkers for HPP [25,29,30]. The challenge of using these 
biomarkers for diagnosis arises from imprecise thresholds. 
Although ALP is routinely measured in metabolic bone clinics, low 
ALP levels may not be flagged as abnormal and could be disregarded 
[25,26,31]. While persistently low ALP activity is a clear diagnostic 
indicator for HPP (supported by our ROC analysis and other data) [25], 
alternative causes of low ALP activity, such as Cushing syndrome, hy-
pothyroidism, multiple myeloma, osteogenesis imperfecta type II, or 
treatments such as glucocorticoids and antiresorptive drugs, should be 
excluded [25,32]. In addition, a recent study investigating patients with 
osteoporosis and low-serum ALP activity (16/3285 or 0.5% of bone 
clinic patients) found a relatively high prevalence of pathogenic variants 
in ALPL (87.5%) among these patients [33]. However, unlike patients 
with HPP, those with osteoporosis and low-serum ALP activity were not 
found to have any distinguishing clinical or biochemical characteristics 
[33]. 
The reliability of low ALP activity alone as an indicator of HPP has 
been found to be inconsistent in a larger, general population [34]. 
Therefore, clinical presentation and other biochemical markers along-
side low ALP activity are more likely to make the diagnosis of HPP more 
robust. Notably, in this study, when used together, total ALP activity of 
43 IU/L or less and PLP levels above 120 nmol/L were able to fully 
discriminate patients with HPP from those with low BMD. It is of interest 
that the PLP threshold value of 120 nmol/L determined in this study is 
close to the estimate for the upper limit of the reference interval for PLP 
established in the large National Health and Nutrition Examination 
Survey (NHANES) that was recently published [35]. It is also important 
to note that PLP is not always elevated in HPP. Other studies have re-
ported that only 50% of patients with HPP have elevated PLP levels 
[34,36]. 
This study also evaluated laboratory markers other than ALP and PLP 
that may assist in distinguishing patients who have HPP from those who 
do not have HPP but present with similar symptoms. BAP was assessed 
in this study; however, its use as a diagnostic marker was not as strong as 
ALP and PLP. In addition, bone resorption markers, such as CTX and 
TRACP5b, were assessed in this study, but were within normal limits 
among patients with HPP and were significantly lower in the low-BMD 
group. This difference may be due to bisphosphonate therapy, as 61.9% 
of the patients in the low-BMD group were taking bisphosphonate 
therapy for osteoporosis. Phosphoethanolamine (PEA) was not assessed 
in this study, because other studies have found PEA to be a less reliable 
diagnostic marker of HPP than PLP. Although inorganic pyrophosphate 
(PPi) is a reliable diagnostic marker of HPP, it was not assessed in this 
study, because it is currently assessed only in research settings [25,37]. 
Functional assessments showed that patients in the HPP group had 
similar physical function and strength based on the SPPB and hand grip 
strength tests when compared with patients in the low-BMD group. 
Although functional burdens due to HPP in adults are comparable with 
Fig. 3. Violin plots of laboratory thresholds in the HPP and low-BMD groups. 
A) All the patients with HPP had a total ALP activity of 43 IU/L or lower; 2 
patients in the low-BMD group were below this threshold. 
B) All patients with HPP had PLP above 120 nmol/L; 18 of 21 patients in the 
low-BMD group had PLP below 120 nmol/L. 
ALP, alkaline phosphatase; BMD, bone mineral density; HPP, hypo-
phosphatasia; PLP, pyridoxal-5-phosphate. 
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the burdens caused by osteoporosis, adult patients with HPP do not have 
as much support or the benefit of wide public health awareness as pa-
tients with osteoporosis do. 
The resemblance of HPP to rheumatological and bone fragility dis-
orders such as osteoporosis suggests that osteoporosis clinics and 
metabolic bone centers may have a notable prevalence of undiagnosed 
HPP. An observational study found that patients with suspected, un-
recognized HPP presented with a higher prevalence of rheumatologic 
conditions, including chondrocalcinosis, calcific periarthritis, enthes-
opathy, and diffuse idiopathic skeletal hyperostosis when compared 
with controls who had normal serum ALP activity (defined as 40 to 125 
IU/L) [26]. 
Biochemical characteristics in patients with confirmed HPP may 
vary. Therefore, the identification of threshold values for ALP and PLP 
and the precise quantitation of these biomarkers in this study may be 
useful for screening patients in general, especially for screening patients 
who attend a metabolic bone clinic, as there may be an increased 
prevalence of HPP in this population due to misdiagnosis or missed 
diagnosis. 
This study is limited by the single-center nature of the study design. 
Because patients with HPP are typically younger than those with oste-
oporosis, it was difficult to individually match patients by age; thus, the 
groups were comprised from the pool of patients who were available via 
the Sheffield Metabolic Bone Centre and RUDY platform. In addition, the 
small sample size may limit generalizability of these findings to other 
settings or patient populations. We appreciate, in particular, that the 
thresholds are based only on 41 patients and so the estimates are subject 
to a large degree of uncertainty and need to be confirmed by future 
studies. Despite these limitations, findings of this study will hopefully 
contribute to improvements in accurate and timely diagnosis of adult 
patients with HPP, thereby reducing the likelihood of misdiagnosis and 
potential harm from bisphosphonate use in these patients. 
5. Conclusion 
The lack of disease awareness and the overlap of HPP symptoms with 
other, similar and more well-known disorders is a major contributing 
factor to the underdiagnosis or misdiagnosis of HPP in adults. This study 
showed that biochemical tests for PLP and total ALP performed well at 
distinguishing HPP from osteoporosis in patients attending a metabolic 
bone clinic. Total ALP and PLP values were found to be the most suitable 
diagnostic biomarkers for HPP in adult patients. These biochemical 
markers, along with key clinical features, such as the presence or history 
of lower-extremity fractures, showed promise for assisting in the timely 
and accurate identification and diagnosis of HPP in patients attending 
metabolic bone clinics. 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.bone.2020.115795. 
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